March 31st, 2020 Posted by Requirements Management Tool 0 thoughts on “INTRODUCTION TO MDSAP (02 Continued)”

MDSAP Pilot Program Participating Countries

Representatives from the following international coalition of countries participated as pilot developers in the MDSAP pilot program:

  • The Australian Therapeutic Goods Administration  (TGA)
  • Brazil’s Agencia Nacional de Vigilancia Sanitaria (ANVISA)
  • Health Canada
  • U.S Food and Drug Administration (FDA) and
  • Japan

International Regulatory Authorities Participation

Every Regulatory Authority that participated in the MDSAP pilot program were considered to be equal partners. The results obtained from the final MDSAP pilot report are based on data accumulated over the course of the three-year pilot. It is expected that more Regulatory Authorities will participate in MDSAP and become active participants in either the pilot program or the implemented MDSAP program.

The observer status and role of European Union were discussed. However, the EU’S participation was declined and this could have been ascribed to the number of member  countries in the Union.

Observers of the MDSAP Pilot Program

MDSAPJapan’s Ministry of Health, Labour and Welfare (MHLW) together with the Pharmaceutical and Medical Devices Agency (PMDA) were observers to the Regulatory Authority Council (RAC) and Subject Matter Expert (SME) in 2013.

The World Health Organisation (WHO) was also an observer to the SME Working Group whereas the European Union participated as observer Status in 2014.

For IVDs pre-clearance process, WHO serves as a member of the IMDRF-MDSAP working group and as an observer to the MDSAP. WHO has shown a willingness to adapt and inculcate MDSAP processes to a certain extent in their pre-qualification program.

MDSAP – Roles of Participants and Observers

MDSAPMDSAP roles involve both participants and observers. Below are their roles explained in detail.


  • The Regulatory Authority participants provide the resources to support the development,  implementation, maintenance and expansion of MDSAP.
  • The Regulatory Authority participates actively in the process of recognizing, monitoring and re-recognizing Auditing Organizations under the framework of the IMDRF and MDSAP.
  • The participating Regulatory Authorities have committed to the use of MDSAP deliverables during the pilot in order to assess program success.
  • Each Regulatory Authority participant is also represented by two senior level managers or the MDSAP Regulatory Authority Council  (RAC) which is the MDSAP’s governing board.


  • A Regulatory Authority who is an observer may attend MDSAP, SME, WG meetings, assessments and other activities but are not to utilize MDSAP program deliverables to replace or supplement it’s regulatory scheme deliverables of let portions of these deliverables.
  • The observers are represented on the MDSAP RAC by one senior level manager.

Pilot MDSAP “Criteria for Success”

The MDSAP Subject Matter Experts Working Group came up with a plan to gather evidence for a “Proof of Concept” of the MDSAP pilot.

There are 8 performance indicators to determine the success of  the pilot. The criteria for success based upon audit reports and nonconformities. These criteria use a method for data collection, sampling method of analysis and Targets which were defined for each indicator.

More information on these criteria can be seen in MDSAP P0007 Proof of Concept for MDSAP pilot document.

How the MDSAP Pilot Audit was Conducted

MDSAP Pilot audit will be conducted by an Auditing Organization according to the FDA. This will be done through the use of  applicable documents developed by the participating Regulatory Authorities for the implementation of the program pilot.

The following policies and procedure were detailed by the FDA on their website:

  • Auditors must follow the sequence of tasks specified in the audit model- MDSAP AU P0002 in order to ensure consistency across auditor teams and auditing organizations.
  • The auditing organization determines the audit duration based on planned audit tasks – MDSAP AU P0008 in order to ensure consistency across auditing organizations.
  • The audit duration will not exceed the accumulated time of multiple audits and inspections they would undergo if the participating Regulatory Authority perform their inspections according to their governing policies.
  • The auditing organization writes an audit report for each audited site using a standard fillable template specifically designed for medical device regulatory audits.
  • Nonconformities identified during an audit are graded on a scale from 1 (least critical) to 5 (most critical) according to explicit criteria – GHTF/SG3/N19.
  • High-grade nonconformities may trigger the performance of an unannounced audit.
  • The manufacturer provides, and the auditing organization reviews, remediation plans and evidence of implementation of these plans according to a specified timeline- MDSAP AU P0027.
  • Auditing organizations will share the audit outcomes with the participating Regulatory Authorities to support their pre-market and post-market programs.
  • Upon successful certification audits, auditing organizations issue MDSAP – SPECIFIC certification documents stating compliance to MDSAP audit criteria – MDSAP AU P0026

MDSAP Pilot Grading System

The MDSAP grading system eliminates the classification of major and minor conformities that the IS auditing system instituted. With the MDSAP grading system, there are no longer majors and minors concerning nonconformities. Instead, the MDSAP grading system uses a 5-point grading scale which ranges from 1 (LEAST critical) to 5 (MOST critical). For more information you can access the GHTF/SG3/N19:2012 (Review the last two pages).

MDSAP Pilot: Mid-point Status Report

This represents was released in August, 2015. It revealed that 45 manufacturers had registered to participate as of July of 2015.

The FDA faced challenges in trying to get companies that dealt in medical devices to sign on to MDSAP. These challenges could have been due to the fact that there were only few qualified auditing organizations available to carry out the audit.

The FDA states in the report that “As more Auditing Organizations become authorized to conduct MDSAP audits, a continuation of the positive slope is anticipated. It is too early to project whether target goals will be met”.

Under MDSAP, only organizations recognized by the Canadian Medical Devices Conformity Assessment System (CMDCAS) are authorized to carry out audits.  There were 13 CMDCAS registrars identified as eligible to participate in the MDSAP pilot and only 6 organizations had signed up and undergone application review and assessments as at July, 2015. By the conclusion of the MDSAP pilot, all 13 organizations had completed these assessments.

Another factor to participation may have been that if an organization had a notified body that was not approved for MDSAP audits, they would need to have another assessment in addition to the regular ISO 13485 audit.

The proof of concept criteria goal was 10% participation level which translates to about 330 manufacturing companies for the MDSAP pilot.

Who Performs the MDSAP audit?

Only approved organizations could apply during the MDSAP pilot. In total, there were only 11 of them. However, at the end of the pilot application, other organizations were being accepted for the consideration for the approval to perform MDSAP audits.

An organization must submit an application to the MDSAP and be approved in order to be recognized by the program as an approved auditor.

MDSAP Pilot: List of Auditing Organization Participants

The following auditing organizations participated in the MDSAP pilot:

  • bsi group America Inc.
  • DEKRA Certification bv
  • DQS
  • Interested testing services NA Inc.
  • Laboratoire National De Métrologie et D’essais GMED Certification division
  • Lloyds Register Quality Assurance Inc.
  • National Standards Authority of Ireland (NSAI)
  • QMI SAI Canada Limited
  • TUV Rheinland of North America Inc.
  • TUV SUD America Inc.
  • UL Medical and regulatory services

Expected Improvements from Implementing MDSAP Pilot Program Audit Model

The MDSAP Pilot was expected to improve the predictability of audit outcomes through:

  • The use of standard MDSAP audit model by multiple international regulatory authorities and auditing organizations
  • Enhanced auditing organization recognition criteria
  • Monitoring of Auditing Organizations by the participating Regulatory Authorities
  • The grading of any nonconformity using objective criteria to characterize the significance of the finding
  • The reporting of the audit outcomes using a standard report template.

We are sorry to see you go

March 21st, 2020 Posted by Requirements Management Tool 0 thoughts on “We are sorry to see you go”


Enter Your Email Address




March 21st, 2020 Posted by 21 CFR part 820, ISO 13485, MDSAP 0 thoughts on “INTRODUCTION TO MDSAP (01)”

What is MDSAP?

MDSAP stands for Medical Device Single Audit Program. It was a program that was created as an alternative to FDA auditing in conjunction with international regulators. With MDSAP, there is an opportunity to participate in international auditing for five different countries. The countries include Australia, Canada, Brazil, the US, and Japan. As it relates to the current COVID-19 crisis, the MDSAP can allow you to navigate your operation between regions and prepare your recovery to a full operation based on the recovery of countries you have participated in.

The MDSAP helps to fulfill the role of providing a single regulatory audit for all medical device manufacturers’ quality management systems. Also, the MDSAP meets all the laws and regulations required in several international jurisdictions. With the MDSAP companies can develop acceptable audits by FDA standard and reduce the number of auditory inspections and expedite the recovery of your manufacturing in the sequence of the recovery of your MDSAP covered regions.

It is crucial to note that only recognized organizations can conduct the MDSAP. Likewise, manufacturing companies can choose to voluntarily join the MDSAP pilot program. The program aims to be recognized internationally for participating countries. The pilot program kicked-off in 2014 and concluded in 2016. More detail about the MDSAP pilot program will be highlighted in this series.

International Regulators: IMDRF

It is no secret that international regulators have been seeking a standardized global approach to the monitoring and auditing of medical device manufacturing companies. In the last ten years, the community of international regulations has taken significant steps to build a sustainable framework. Leveraging works from previous organizations like the Global Harmonization Task Force, the International Medical Device Regulators Forum (IMDRF) have spearheaded the efforts in the creation of this framework. As a result, they were able to develop explicit criteria for MDSAP.

Who is Responsible for the Creation of MDSAP and MDSAP Pilot Program?

The people/parties responsible for the creation of MDSAP and MDSAP pilot include;

  • The IMDRF Management Committee (MC) regulators consist of representatives from China, Brazil, EU, Australia, Russian, Canada, Japan, and the US.
  • Observers from the Asia Pacific Economic Commission Life Science Innovation Forum (APACLSIF) and the World Health Organization (WHO).
  • Affiliate Organizations like the Pan-American Health Organization and the Asian Harmonization Working Party.
  • Working Groups like the IMDRF that produce standards, MDSAP, Submissions, UDI, MCAR software.


International Medical Device Regulation Forum

MDSAP is the fruit of over 10 years of planning by International regulators responsible for the IMDRF. The IMDRF is a group of voluntary medical device regulators from various parts of the world. They often gather to discuss the future and plans for medical device regulatory convergence and harmonization.

The IMDRF also discuss the following subjects when they convene;

  • The acceleration of international medical device regulatory harmonization and convergence.
  • The requirements and documentation needed for both MDSAP and MDSAP Pilot.


History of IMDRF

In February 2011, the International Medical Device Regulation Forum (IMDRF) was born. Similar to other international regulatory groups, IMDRF recognizes the impact of having a global approach for auditing and overseeing medical device manufacturers.  With a global approach, they could enhance both oversight and safety on an international scale.

The first meeting of the IMDRF took place in Singapore in 2012. During the meeting, the group selected a workgroup with the sole purpose of developing documents for a single audit of the program. The single audit program is the MDSAP and as a result, they launched the MDSAP pilot study.


IMDRF and MDSAP Requirements/Documentation

The IMDRF workgroup made sure that MDSAP had documents that cover the following;

  • Initial recognition surveillance and recognition criteria for MDSAP-Recognized Organizations (AO).
  • Standardized Recognized Audit Organizations, auditor competency, and competency maintenance requirements.
  • Standardized regulatory authority assessor competency and competency maintenance requirements.
  • Standardized audit and assessment models
  • Auditing of a manufacturer by an MDSAP-Recognized AO.
  • Assessment of MDSAP Recognized AO’s by participating Regulatory Authorities.


The purpose of the MDSAP Pilot

The purpose of the MDSAP Pilot is as follows;

  • To pilot the implementation of the requirements that are defined in the IMDRF MDSAP model.
  • Enable appropriate regulatory oversight of the medical device manufacturer’s quality management system while minimizing the regulatory burden on the industry.
  • To promote more efficient and flexible use of regulatory resources through work-sharing and mutual acceptance among regulators while respecting the sovereignty of each authority.
  • To globally promote greater alignment of regulatory approaches and technical requirements based on international standards and long-standing practices.
  • To promote consistency, predictability, and transparency of regulatory programs by standardizing the practices and procedures of participating regulators with the oversight of third-party auditing organizations.
  • To standardize the practices and procedures of participating third-party auditing organizations.
  • To leverage where appropriate, the existing requirements and procedures for conformity assessment.


The MDSAP Pilot Timeline

Between the periods of January 1st, 2014 to December 31st, 2016, the FDA and other participating international regulators were part of the Medical Device Single-Audit Program Pilot. A report detailing the outcome of various perspectives, criteria, and proof-of-concept, to establish the viability of the MDSAP Pilot Program. The report was released on June 29th, 2017. The outlined outcomes were based on the foundational data gathered during the three-year pilot phase.

The final outcomes are as follows;

  • Both the International MDSAP governing body and the MDSAP Regulatory Authority Council agree that the MDSAP Pilot sufficiently demonstrates its viability for the Medical Device Single Audit Program.
  • A fully operational MDSAP was to be in effect in 2017 following a successful conclusion to the pilot at the end of 2016.
  • Canada decided to accept MDSAP rather than CDMAS in January of 2019.


The MDSAP Timeline

In 2012, the IMDRF launched the Medical Device Quality Audit Program. The goal of this initiative to pool resources together and ensure the safety of medical devices sold to the customers. The IMDRF put up a working group to cater to the details of the program. The MDSAP program has its foundations in various international standards and procedures. Some of which include;

  • ISO 13485: 2003 now become 2016
  • The Brazilian Good Manufacturing Practices (RDC ANVISA 16/2013)
  • The US Quality System Regulation (21 CFR Part 820)
  • Other specific pre and post-market regulatory requirements if the authorities of various participating members of the group.

Based on these foundations Orcanos creates a state of the art eQMS platform that handles all product lifecycle stages in one single system. Just as the single auditing system impacts the acceleration of innovation, the Orcanos single processing system is able to integrate natively with the Design Control, Quality, Regulation, and Manufacturing.

Related Topics

MDSAP Series of Articles Overview Support during the COVID-19 pandemic


MDSAP Series of Articles Overview

March 20th, 2020 Posted by Requirements Management Tool 0 thoughts on “MDSAP Series of Articles Overview”

How MDSAP Can Help you Get out of Covid-19 era Faster Than Anyone

The purpose of this MDSAP series of articles is to examine the process of preparing and applying for the Medical Single Audit Program (MDSAP). The series is outlined in a way that benefits any medical device company that is planning to join or just joined the MDSAP program. Additional benefits include an overview of the program and links to more resources on certain topics.

The purpose of this series of articles  is to help medical device companies understand the following;

  • The Audit Process and History of the Program
  • The necessary company preparation that This for applying to MDSAP.

The learning objectives of this series of articles  are as follows;

  1.     The goals of MDSAP
  2.     International Regulators
  3.     The history of the IMDRF
  4.     The MDSAP Pilot program basics
  5.     The MDSAP Audit Model
  6.     The primary processes of MDSAP
  7.     MDSAP and ISO 13485
  8.     MDSAP Audit Structure

Who Should Read This Articles?

The MDSAP series of articles is for people in the Life Science industry that are responsible for quality assurance, quality control, or the implementation of a quality management system in accordance with ISO 13485 2016, and preparing for is an MDSAP audit. Below is a glossary of terms you are likely to encounter in this series of articles.

As well as global operation companies who may need to move some operations across sites under the same single audit program.


ANVISA: Agencia Nacional de Vigilancia Sanitaria (Brazil)

AO: Auditing organization

CMDCAS: Canadian Medical Devices Conformity Assessment System

CRO: Contract Research Organization

DUNS: Data Universal Numbering System

EU: European Union

FDA: Food and Drugs Administration (USA)

GHTF: Global Harmonization Task Force on Medical Devices

IMDRF: International Medical Device Regulators Forum

IVD: In-Vitro Diagnostics

MAH: Marketing Authorization Holder (Japan)

MDAP: Medical Device Application Procedure

MDSAP: Medical Device Single Audit Program

MHLW/PMDA: Ministry of Health Labor and Welfare/ Pharmaceuticals and Medical Devices Agency (Japan)

NC: Non-Conformity

PMA: Pre-Market Approval

eQMS: Electronic Quality Management System

QSIT: FDA Quality System Inspection Technique

RAC: Regulatory Authority Council

SME: Subject Matter Experts

TGA: Therapeutic Goods Administration (Australia)

UDI:  Unique Device Identification

ALM: Application Life Cycle Management (SDLC) – Design Control

WHO: World Health Organization

Orcanos: Design Control and Quality Cloud Platform


Series of articles Modules

There are 6 modules in the MDSAP series of articles. They are;

  1. Introduction to MDSAP
  2. The MDSAP Audit Model Overview
  3. Preparing for MDSAP Audit Process 
  4. The MDSAP audit
  5. MDSAP Roles and Responsibilities During the Audit
  6. Benefits and Future of MDSAP

To get started, we will be going over modules 1 and 2.

Please stay tuned and follow our next articles on this series INTRODUCTION TO MDSAP.

Related Topics:







Support during the COVID-19 pandemic

March 18th, 2020 Posted by Automotive, Collaboration, How to, KPI, Requirements Management Tool, Tip Of The Week, Tips 0 thoughts on “Support during the COVID-19 pandemic”

The coronavirus pandemic has shuttered schools, canceled major events, disrupted travel, and interrupted many business services we take for granted. Orcanos is working tirelessly to provide all the support and resources we can to help our global customers during this difficult time.

Virtual Events

Click to add to Google Calendar:

March 19 (16:00 GMT+2)

Click to add to Google Calendar:

March 23 (16:00 GMT+2)

Click to add to Google Calendar:

March 23 (16:00 GMT+2)

Click to join the Zoom Calendar:

Click to join the Zoom Calendar:

Click to join the Zoom Calendar:

Zoom Meetings for Medical Device

Zoom Meetings for Automotive

 Best Practice Working from Home using Orcanos

Learn how Orcanos best in class help you stay in touch with your customers and conduct a complete PMS process. Learn how to automate your processes and control and governance your work to comply with the ASPICE process. Join experts from Orcanos to more effectively use technology to work from home.

1 Remote Working

The coronavirus pandemic has transformed many organizations into fully remote operations, but managing the change isn’t always easy. We’re here to help. Orcanos gives the ability to collaborate using the devices you already have, providing a comprehensive resource for anyone working from home.


2 Compliance & Governance

Many quality personal are scrambling to move their audit online as their offices around the world temporarily shut down. We’re making sure quality and regulation engineers, production line, customer service, and employees around the world can spin up remote quality events, participate in online design reviews, and successfully use Orcanos for e-signator approval.

Orcanos is helping by lifting the 40-minute training sessions on customers affected by the coronavirus












Are you ready to take the next step to paperless world….

March 15th, 2020 Posted by Requirements Management Tool 0 thoughts on “Are you ready to take the next step to paperless world….”

Who would have think that far…

Already 5 years ago someone tried to spread this idea that our current efforts are not pointing to the right place. He is talking about many important things, there is no one solution for all but it was easy to identify some pitfall on our current state. For over 15 years Orcanos is building solutions around collaboration and speeding up the data process among teams and external organizations. It was already said one of the blockers to the cancer disease if the knowledge that is captured by the paper that can not be processed or analyzed or transferred.

Orcnanos paperless system for both R&D and QMS is just part of the overall solution needed for the fast transfer of data and knowledge between different regulatory bodies and medical device vendors. Our solution already operating in large enterprises such as GE, J&J, and Medtronics as well on many other SMB’s helping them to collaborate across continentals and groups.

It is time to concentrate on the right infrastructure of your organization and equip your team with cloud base tools that are easily accessed to streamline your data.



January 26th, 2020 Posted by ISO 14971, Requirements Management Tool 0 thoughts on “RISK MANAGEMENT (05) – FMEA GENERAL OVERVIEW”

In this post, we will be sharing the basic information that you as a medical device manufacturer should know about Failure Mode and Effect Analysis (FMEA).

What is FMEA?

FMEA stands for Failure Mode and Effect Analysis. One can describe as a continuous quality process that helps to identify potential manufacturing and design errors. Furthermore, FMEA helps to determine the effects of these errors before they actually happen. As a result, if a medical device company suspects vulnerability in their system or process, FMEA is an inductive and proactive way to logically get to the root cause of the problem and develop solutions. In simple terms, it is a way to estimate what could go wrong and develop a prevention plan. FMEA can be simplified as follows;

Failure Mode: The stage of contemplating what is wrong with a product? Or how a processor device can fail?

Effect: What will be the result of the failure in the product or process? How would it impact a patient, the company and overall performance?

Analyze: Discover the root cause of the failure as well as the chances of it occurring before there is an actual incident.

Firstly, below are the 9 major advantages of a comprehensive FMEA.

Advantages of FMEA

  1.   An effective FMEA will lead to improved quality, upper reliability, and enlarged safety.
  2.   It makes it easier to develop ideas and concepts that will help improve similar processes and designs
  3.   Using FMEA will allow companies to improve both manufacturing and design efficiencies.
  4.   It allows for proper documentation of Corrective Action implementation that led to improvements.
  5.   It helps to remove or eliminate the possibility of late changes and the crisis it brings.
  6.   It reduces the chances of repeating similar of the same mistakes in the long-term.
  7.   It helps to lower the cost and time need for system development.
  8.   It allows for co-operations between co-workers at all levels. As a result, there is a better exchange of ideas and teamwork.
  9.   Companies get the benefit of improving their market competitiveness and overall image.

 FDA Endorsement

In several industries, one of the most efficient ways to analyze reliability problems in the early stage of product development is through FMEA. Due to FMEA, manufacturers can act proactively toward reducing or removing potential failure.

One of the tools that the FDA endorses to help manufacturers deal will medication errors is FMEA. It is worth noting that prevention is always better than cure.

 The Origins of FMEA

We can trace the history of FMEA back to NASA in the 60s when the organization was concerned about the safety and reliability of space program hardware. Since that time, any industries with a reputation for high-cost or high-risk makes use of FMEA. As of today, the FMEA method is commonly used in the medical device and pharmaceutical industries.

FMEA method is an effective way to identify potential errors, failures and problems in the design, systems, processes and service before customer consumption. Making it easier to implement and document corrective actions. In the ICH Quality Rick Management Q9 guide, FMEA is the primary tool listed for Quality Risk Assessment.

 The ICH Quality Risk Management Q9 Guide

According to Section 1.12 of the ICH manual, FMEA is;

  • FMEA (IEC 60812) opens an opportunity to evaluate various modes of potential failure and predict the possible effects it will have on product performance.
  • Once failure modes are determined, it is possible to use risk reduction to reduce, remove or control likely failures. However, it works when there is a proper understanding of the process and product development.
  • With the help of FMEA, a company can break down the analysis of complex processes into gradual steps methodically. It is a tool that allows for the summarizing of crucial failure modes, the factors responsible for the failure and their possible effects.

In determining the use of FMEA, it is possible to use FMEA to prioritize risks, while monitoring the effects of various control measures. Likewise, it can be used in various equipment and manufacturing facilities. Similarly, it can be used to pinpoint high risk and critical requirements in various system and process development cycles.

The relative risk score is the output of an FMEA process and it is used to rank various failure modes by their potential risk threat.

 Application of FMEA in the Pharmaceutical Industry

The most popular risk management methodological term is FMEA. As a result, it features in numerous instances. For example;

  1.  When it comes to drug substances and products, it can be used to define the design space for their manufacturing processes. During the design phase, FMEA can help outline design options, select the best one, as well as improve the design and processes.
  2.  It helps with the setup of both the manufacturing and design of equipment. Also, it aids the optimization and improvement of qualification and maintenance plans for equipment. If a device, process or system can fail then you can apply FMEA to it.

 What can FMEA do for you?

Below are some of the benefits of applying the FMEA method in your manufacturing processes;

  • It will assist you in discovering and analyzing likely failures mores ahead of time.
  • You will be able to quantify the effects of those potential failures.
  • It will help you estimate the probability of having the failure modes occur.
  • Using FMEA, you will be able to identify as well as prioritize corrective actions that will result in the reduction or removal of the potential failure threat.
  • It is a valid way of documenting and implementing plans that will reduce risks in a system.

Therefore, we can summarize that effective FMEA helps to enhance the safety, quality, and reliability of a developmental process. In doing so, the company will be able to save time and money while ensuring customer satisfaction.

So, with FMEA, you can create time to handle other pressing activities while saving cost and time on risk management.

When to Perform FMEA?

FMEA can be conducted at the following times;

  1.   When you start a new product cycle.
  2.   When there is an update in the current design, system or processes.
  3.   There is a change in the operating parameters of a system.
  4.   A current process or design is been used for something different.
  5.   There are new regulations governing a design, process, system or product use.
  6.   When customer feedback point to a problem.
  7.   When analyzing failures in an existing system or process.

Therefore, make it a rule to systematically and periodically perform FMEA throughout the life cycle of a system, design or product. That way, there is a way to track updates, improvements and threats to the process. It is crucial to deal with RISK NOW rather than face FAILURE later.


How to Succeed in the Automotive Industry?

January 19th, 2020 Posted by ASPICE, Automotive, Requirements Management Tool 0 thoughts on “How to Succeed in the Automotive Industry?”

What does it take to succeed in the Automotive Industry? Well, the majority of the stakeholders in the industry agree that success comes with product quality. It is hard to argue the impact that product quality plays in automotive success. Likewise, evidence from surveys shows that when it comes to success and profitability in the world of automotive. Product Quality ranks above other factors.

The Industry Demands Product Excellence Ask people in the Automotive industry what leads to success and you’ll hear that product quality has a major impact. As you might expect, survey respondents report product quality as a profitability and success driver more frequently than any other factor. 

But innovation reported as a profitability driver more frequently by Automotive companies than any other industry in our survey isn’t far behind. Perhaps this isn’t surprising given the major changes facing the industry. 

The top success factors – quality, innovation, reliability, performance, and cost – are all related to product excellence. But today’s dynamic market also demands agility. In fact, OEM’s were almost twice as likely as suppliers to report time-to-market as a critical success driver. 

The ALM & QMS, Together, Delivers Product Excellence and Agility Our research shows that an effective ALM & QMS can help improve all of these factors. These platforms, incorporating engineering tools (ALM) and QMS capabilities, are proven to drive better product development results. The cloud is reducing the barriers between these ALM & QMS solutions and provides benefits in multiple dimensions, including affordability, flexibility, and agility. We explore these further in the research. 

Most Important Factors to Automotive Industry Success & Profitability

Success Rate


If you are looking to leverage on the factors that will drive your company to success. Reach out to us at Orcanos and we will show you how to enhance your product while reducing the cost. After working with us, you can be sure that you will be a symbol of innovation in the automotive market.


  • Product Quality is vital to the success of an automotive company
  • The factors to success in the industry can be summarized as agility and product excellence.
  • ALM and QMS tools will allow companies to achieve product excellence.
  • The cloud makes ALM and QMS tools easy and affordable to use.
  • Orcanos is the company to meet for help with how to leverage cloud and


Why Automotive Industries Uses Product Innovation Cloud Platforms?

January 15th, 2020 Posted by Requirements Management Tool 0 thoughts on “Why Automotive Industries Uses Product Innovation Cloud Platforms?”

Product Innovation Platforms

ALM & QMS Innovation Platform

According to an industry survey, we can define Application and Quality Innovation and Manufacturing Software as a software to support product lifecycle covering the following;

  • Manufacturing Execution Systems (IMES)
  • Quality Risk Management (QRM)
  • Computer Requirement Management System (RMS)
  • Training Management System
  • Verification and Validation System (V&V)
  • Product Lifecycle Management
  • Electronic Device History Records (eDHR)
  • Document Control System (DMS)

Evolution of ALM & QMS Innovation Platforms

It is crucial to understand the development and growth of ALM & QMS solution before exploring cloud opportunities. Thanks to engineering solutions, companies can design innovative products. Also, it is possible to simulate and model manufacturing methods, new materials, systems and any other factor that will aid product prediction and behavioral analysis. Not less important is our we asses those impacts and translate them into the RISK management system and prediction of possible results if we do not address them correctly.

To support programs, products, and processes, automotive engineering tools are fused with process management solutions and data.  With the aid of Orcanos ALM and QMS tools, companies can analyze various support systems on their product from the idea stage to launch.

The Demand for Digital Enterprise

The demand for digital transformation in the manufacturing sector continues to grow. As a result, solutions need to have model-based systems, data-driven design, and integrated engineering.  Similarly, it is crucial that there is overall support in the digital community to embrace various engineering fields so they can collaborate to building a cohesive model when it comes to design.  Furthermore, there has to be secure collaboration on all domains in real-time, anytime and anywhere.

Orcanos ALM and QMS offer a more comprehensive digital solution and solution. It eliminates the problems with the file-base systems and comes with a cloud package.

Requirements Traceability from the Cradle to the Grave

January 1st, 2020 Posted by Requirements Management Tool 0 thoughts on “Requirements Traceability from the Cradle to the Grave”

Requirements traceability from the cradle to the grave is the key to quality in our development of medical device systems. Orcanos gives us this tracking ability and provides us with high flexibility, comprehensive reports along with good office integration. This enables us to implement our workflow effectively.

With Orcanos, we have one tool that supports our way of working and gives good visibility to our KPI’s and internal operational status. We now have a tool that can be customized to exactly our requirements and provides quality feed-back, making regulatory submission more integrated and streamlined.

Jason Reece, CTO of Genomtec

Page 1 of 20
1 2 3 20


8 Tozeret Ha'aretz Street
Tel Aviv, Israel

Copyright © Orcanos, All rights reserved. | Privacy policy | Terms of use